Vident Advisory LLC Has $495,000 Stake in Grifols, S.A. $GRFS

Key Points

• Vident Advisory LLC increased its stake in Grifols, S.A. by 134.5% during the 1st quarter, now owning 69,564 shares valued at $495,000.
• Grifols recently declared a special dividend of $0.1404 paid on August 20th, reflecting a payout ratio of 11.97%.
• The stock price of Grifols has risen by 2.3% recently, with a current price of $10.13 and an average price target of $10.30 from analysts.

Vident Advisory LLC lifted its stake in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 134.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 69,564 shares of the biotechnology company's stock after purchasing an additional 39,902 shares during the quarter. Vident Advisory LLC's holdings in Grifols were worth $495,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Grifols by 4.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 46,078 shares of the biotechnology company's stock valued at $328,000 after purchasing an additional 2,026 shares during the period. Sequoia Financial Advisors LLC boosted its position in shares of Grifols by 14.9% in the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock valued at $186,000 after purchasing an additional 3,399 shares during the period. Versant Capital Management Inc acquired a new position in shares of Grifols in the 1st quarter valued at $28,000. Cerity Partners LLC boosted its position in shares of Grifols by 22.8% in the 1st quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 4,129 shares during the period. Finally, Cetera Investment Advisers boosted its position in shares of Grifols by 16.1% in the 1st quarter. Cetera Investment Advisers now owns 35,254 shares of the biotechnology company's stock valued at $251,000 after purchasing an additional 4,900 shares during the period.

Analyst Upgrades and Downgrades

GRFS has been the subject of a number of recent analyst reports. Wall Street Zen upgraded Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 7th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Grifols in a research report on Tuesday, August 5th. JPMorgan Chase & Co. raised their price objective on Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research report on Tuesday, June 17th. Finally, Zacks Research upgraded Grifols to a "hold" rating in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Grifols currently has an average rating of "Moderate Buy" and a consensus price target of $10.30.

Grifols Stock Down 1.6%

Shares of Grifols stock traded down $0.16 during trading on Friday, hitting $9.88. 359,935 shares of the stock traded hands, compared to its average volume of 510,927. The stock has a market cap of $6.79 billion, a P/E ratio of 8.44, a PEG ratio of 0.34 and a beta of 0.64. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.95 and a current ratio of 2.64. Grifols, S.A. has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a fifty day moving average price of $10.09 and a two-hundred day moving average price of $8.64.

Grifols Announces Dividend

The company also recently declared a special dividend, which was paid on Wednesday, August 20th. Stockholders of record on Tuesday, August 12th were issued a dividend of $0.1404 per share. The ex-dividend date was Tuesday, August 12th. Grifols's payout ratio is currently 11.97%.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.